Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
QuintilesIMS
McKinsey
Dow
Healthtrust
US Department of Justice
Boehringer Ingelheim
McKesson
Moodys
Accenture

Generated: February 21, 2018

DrugPatentWatch Database Preview

GELNIQUE 3% Drug Profile

« Back to Dashboard

When do Gelnique 3% patents expire, and what generic alternatives are available?

Gelnique 3% is a drug marketed by Allergan Sales Llc and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and fifteen patent family members in twenty-two countries.

The generic ingredient in GELNIQUE 3% is oxybutynin. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxybutynin profile page.
Summary for GELNIQUE 3%
International Patents:115
US Patents:4
Applicants:1
NDAs:1
Clinical Trials: 3
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:GELNIQUE 3% at DailyMed
Drug patent expirations by year for GELNIQUE 3%

US Patents and Regulatory Information for GELNIQUE 3%

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Sales Llc GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for GELNIQUE 3%

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,335,379 Transdermal pharmaceutical formulation for minimizing skin residues ➤ Sign Up
8,652,491 Transdermal compositions for anticholinergic agents ➤ Sign Up
6,743,441 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
7,081,251 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
8,980,290 Transdermal compositions for anticholinergic agents ➤ Sign Up
7,214,381 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels ➤ Sign Up
7,081,252 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
7,087,241 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
7,404,965 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels ➤ Sign Up
7,081,249 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for GELNIQUE 3%

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
UBS
Harvard Business School
Baxter
Medtronic
Chubb
Cerilliant
QuintilesIMS
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot